See the DrugPatentWatch profile for Qulipta
Qulipta and Topamax are both medications used for migraine prevention, but they differ in their mechanisms of action, administration, and side effect profiles.
How do Qulipta and Topamax work for migraines?
Qulipta, also known as atogepant, is a calcitonin gene-related peptide (CGRP) receptor antagonist. It works by blocking the action of CGRP, a molecule involved in migraine pain. Topamax, or topiramate, is an anticonvulsant that is believed to prevent migraines by affecting nerve pathways in the brain. It may also increase gamma-aminobutyric acid (GABA) activity and block glutamate receptors [1].
What are the differences in how Qulipta and Topamax are taken?
Qulipta is taken orally once a day [1]. Topamax can also be taken orally, usually twice a day, and is available in tablet and capsule forms [2].
What are the common side effects of Qulipta?
Common side effects reported with Qulipta include upper respiratory tract infection, nausea, and diarrhea [1].
What are the common side effects of Topamax?
Topamax has a broader range of potential side effects. These can include tingling or numbness in extremities, dizziness, fatigue, drowsiness, nausea, diarrhea, weight loss, and speech problems [2]. Serious side effects can include acute myopia, glaucoma, and certain vision problems. It can also cause hyperammonemia with or without encephalopathy and fetal harm if taken during pregnancy [3].
Are there differences in Qulipta and Topamax clinical trials?
Qulipta's efficacy was demonstrated in two pivotal Phase 3 studies, PROGRESS I and PROGRESS II, which showed significant reductions in monthly migraine days compared to placebo [4]. Topiramate has also been studied extensively for migraine prevention, with trials showing its effectiveness in reducing migraine frequency [5].
Where can I find patent information for Qulipta and Topamax?
Patent information for medications like Qulipta and Topamax can be found on patent tracking websites. For example, information on drug patents and exclusivity can be accessed through DrugPatentWatch.com [6].